[Remote] Senior Director, Field Medical Affairs at Amylyx Pharmaceuticals

Cambridge, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

An advanced degree is required, such as a PharmD, MD, PhD, or equivalent
A minimum of 10 years of relevant experience in the pharmaceutical or biotech industry, with at least 5 years in a field medical leadership role with people management responsibilities
Strong understanding of drug development, clinical trial methodology, and industry regulations and guidelines governing field medical activities, including the PhRMA code and FDA promotional guidelines
Experience/expertise in endocrinology/obesity medicine strongly preferred
Proven track record of leadership

Responsibilities

Develop and execute the national field medical strategy in alignment with the broader Medical Affairs and company objectives. Define the vision, set strategic goals, design and report KPIs, and ensure tactical execution across the field team
Recruit, hire, train, and manage a high-performing field medical team. Foster a culture of scientific excellence, accountability, and continuous learning. Provide mentorship, coaching, and career development opportunities to team members
Oversee the team's scientific exchange activities with external stakeholders, including national and regional KOLs, healthcare providers (HCPs), and professional medical societies. Ensure the team delivers timely, impactful data and communicates scientific information accurately and compliantly
Partner closely with internal departments—including Medical Affairs, Commercial, Clinical Development, R&D, Market Access, and Regulatory—to ensure alignment and support for product launches, payer engagements, clinical trial activities, and other strategic initiatives
Establish a process for gathering, summarizing, and disseminating field-based medical insights to internal stakeholders to inform strategic decision-making and identify educational gaps
Ensure all field medical activities adhere to company Standard Operating Procedures (SOPs) and regulatory and compliance guidelines. Oversee operational aspects, including budget management, performance tracking, and the effective use of customer relationship management (CRM) systems

Skills

Key technologies and capabilities for this role

Medical AffairsField Medical StrategyMSL ManagementKOL EngagementTeam LeadershipStrategic PlanningCross-Functional CollaborationPharmaceutical StrategyClinical Development

Amylyx Pharmaceuticals

Develops treatments for neurodegenerative diseases

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Cambridge, MassachusettsHeadquarters

2013Year Founded

$166.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Relyvrio's Phase III failure raises concerns about ALS treatment efficacy.

Low stock offering price suggests potential financial instability.

New CCO may disrupt commercialization strategies if not aligned with goals.

Differentiation

Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.

AMX0035 is a promising drug for ALS and Alzheimer's treatment.

Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Upsides

Positive Phase II results for AMX0035 in ALS boost its potential.

Partnership with Gubra accelerates drug development for neurodegenerative diseases.

Regulatory support for rare diseases aids Amylyx's Wolfram syndrome efforts.

Land your dream remote job 3x faster with AI

Try Jobo Free